SWTX: springworkstx.com Net earnings per share for the last 12 months

Symbol and logo of brand SpringWorks Therapeutics, Inc. (SWTX)

Partner manufacturing capacities for oncology drugs are fully utilized, and the equipment remains in ideal condition. The rolling annual earnings per share help assess business stability, where the current parameter equals -3.41. SpringWorks Therapeutics (SWTX) is developing the innovative inhibitor Ogsiveo by investing in precision molecular design. Specialization in rare pathologies with no alternative treatments grants SpringWorks Therapeutics (SWTX) monopolist status and accelerated regulatory approval.

SWTX (SpringWorks Therapeutics) Net earnings per share (EPS TTM) history from 07/04/2022 to 07/12/2025

Analytical breakdowns for SpringWorks Therapeutics

- share price and expert price forecast:
Stock Quotes SpringWorks Therapeutics|SWTX - Fair Value Consensus
- market capitalization information:
Market Valuation SpringWorks Therapeutics, Inc.|SWTX - Aggregate Business Value
- balance sheet net asset value indicators:
Book Value per Share SpringWorks Therapeutics|SWTX - Book Capitalization|Market Value to Book Value Ratio springworkstx.com|SWTX - Aggregate Asset Value
- business debt structure and liquidity details:
Total Debt to Capital SpringWorks Therapeutics|SWTX - Long-Term Indebtedness to Equity|Short-Term Debt to Capital SpringWorks|SWTX - Company Cumulative Debt|Debt to Book Value SpringWorks Therapeutics, Inc.|SWTX - Amount of Long-Term Liabilities|Company Short-Term Debts SpringWorks Therapeutics|Quick Ratio springworkstx.com
- net income and valuation multiples indicators:
SWTX - Company Profit|Future Profit SpringWorks Therapeutics|SWTX - Company Value to Net Income|Projected Price to Earnings SpringWorks Therapeutics, Inc.|SWTX - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple SpringWorks Therapeutics, Inc.|SWTX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) SpringWorks Therapeutics|SWTX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months springworkstx.com|SWTX - Earnings per share increase in current year|Earnings growth forecast for next year SpringWorks Therapeutics
Basic company analysis:SpringWorks Therapeutics - SWTX
Manufactured products of SpringWorks Therapeutics Inc.

Fundamental asset screening requires separating market noise from actual business performance. This indicator measures net income distributed per share annually, allowing for an objective assessment of equity returns. By analyzing the trend of the rolling 12-month earnings per share, an investor can identify asset overvaluation. For SpringWorks Therapeutics (SWTX), this metric reflects the monetization of developments in rare tumor therapy. The innovative treatment ecosystem for desmoid tumors directly determines the future growth of this indicator.

Who SpringWorks Therapeutics competes with

GMAB: Net earnings per share for the last 12 months|Earnings per share for the trailing year EXEL (exelixis.com)|NUVL (Nuvalent) - Net earnings per share for the last 12 months|KYMR: Earnings per share for the last four quarters|IDYA (IDEAYA Bio) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Enliven Corp|Earnings per share for the last twelve months ORIC Pharmaceuticals (ORIC)|RLAY (relaytx.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) NRIX (Nurix Therapeutics, Inc.)|Net earnings per share for the trailing year Tyra Biosciences Inc|Verastem Inc - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Monte Rosa Corp|CGEM (Cullinan Therapeutics) - Net earnings per share for the last 12 months|IMRX: Earnings per share for the last four quarters|CCCC (C4 Therapeutics) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Black Diamond Therapeutics, Inc. BDTX|Net earnings per share (EPS TTM) RPTX|PMV Pharmaceuticals, Inc - Earnings per share for the last 12 months|Karyopharm Therapeutics Inc. - Net earnings per share for the last 12 months|Earnings per share for the trailing year PPCB|BGMS: Net earnings per share for the last 12 months|Aadi Bioscience - Earnings per share for the last four quarters|ALRN: Net earnings per share (EPS TTM)|Blueprint Medicines Corporation - Earnings per share for the trailing year|GLYC (GlycoMimetics Inc.) - Net earnings per share (EPS TTM)